http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 07:38:43 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/BioLineRx+%28BLRX%29+Reports+In-Line+Q1+EPS/26553570.html <p>BioLineRx (NASDAQ: BLRX) reported Q1 EPS of $0.00. Revenue for the quarter came in at $480 thousand.</p><p>For earnings history and earnings-related data on BioLineRx (BLRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=BLRX">click here</a>.</p> http://www.streetinsider.com/Earnings/BioLineRx+%28BLRX%29+Reports+In-Line+Q1+EPS/26553570.html Wed, 27 May 2026 07:38:43 -0400 BLRX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+May+27/26553459.html si-local-file:///var/storage/secattach/20260527/26553459.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+May+27/26553459.html Wed, 27 May 2026 07:20:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+May+27/26553459.html si-local-file:///var/storage/secattach/20260527/26553459.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+May+27/26553459.html Wed, 27 May 2026 07:20:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+May+27/26553459.html si-local-file:///var/storage/secattach/20260527/26553459.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+May+27/26553459.html Wed, 27 May 2026 07:20:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/Press+Releases/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2 http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html <div class="xn-content"> <p class="prntac"><i>- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment </i><i>of glioblastoma (GBM) -</i></p><p class="prntac"><i>- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -</i></p><p class="prntac"><i>- Management to host conference call today, <chron>May 27</chron>, at <chron>8:30 am EDT</chron> -</i></p><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended http://www.streetinsider.com/PRNewswire/BioLineRx+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26553269.html Wed, 27 May 2026 07:00:00 -0400 A.04794336 A.09408455 A.50216726 A.50216777 BLRX BLRX O.05892620 O.10557543 O.21612337 O.38699866 O.54516537 YP2